Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: Sanofi And GSK’s ‘Tortoise’ Joins Hares In Vaccine Race

Plus: Japan Pledges Support For Covax Initiative

Executive Summary

Initial results from the study are expected in early December 2020, which would allow the start of a Phase III trial before the end of the year.

You may also be interested in...



Gottlieb: Staged Access To Coronavirus Vaccine Possible Through EUA

Former FDA Commissioner says agency could grant an EUA for a vaccine, but require it meet the standard for full approval, and then roll it out gradually with postmarket data collection.

Coronavirus Notebook: EU Joins COVAX, Sanofi/GSK Vaccine Moves To Phase I/II

Convalescent plasma has taken another battering as a potential treatment for coronavirus patients, after a UK drug safety body agreed with a US expert panel that there was not yet enough evidence to recommend its use in COVID-19 patients. 

Analyst Predicts $20bn COVID Vaccines Market In 2021

Analysts have taken a first stab at predicting the size of the COVID-19 vaccine market – in which Pfizer and Moderna are likely to start strong, but could give way to other big players.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142903

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel